We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

92 hedge funds and large institutions have $334M invested in CTI BioPharma Corp. (DE) Common Stock in 2022 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

725% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 4

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

183% more capital invested

Capital invested by funds: $118M → $334M (+$216M)

46% more funds holding

Funds holding: 63 → 92 (+29)

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

22% more call options, than puts

Call options by funds: $3.15M | Put options by funds: $2.57M

Holders
92
Holders Change
+29
Holders Change %
+46.03%
% of All Funds
1.45%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.09%
New
33
Increased
24
Reduced
18
Closed
4
Calls
$3.15M
Puts
$2.57M
Net Calls
+$574K
Net Calls Change
+$72K

Top Buyers

Rank Fund Capital Flow
1
LPC
Lion Point Capital
New York
+$12.7M
2
BL
Bleichroeder LP
New York
+$10.8M
3
Millennium Management
Millennium Management
New York
+$5.88M
4
SI
Sofinnova Investments
California
+$5.82M
5
Two Sigma Investments
Two Sigma Investments
New York
+$4.37M

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$12.3M
2
ACM
Altium Capital Management
New York
-$5.62M
3
CC
Caxton Corporation
New Jersey
-$5.55M
4
Deutsche Bank
Deutsche Bank
Germany
-$2.89M
5
Renaissance Technologies
Renaissance Technologies
New York
-$728K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$1.27M +$173K +58,021 +27%
PPA
27
Parametric Portfolio Associates
Washington
$1.1M +$704K +236,065 New
PHP
28
Parkman Healthcare Partners
Connecticut
$1.05M +$671K +225,000 New
SSA
29
Schonfeld Strategic Advisors
New York
$978K +$115K +38,400 +22%
Jane Street
30
Jane Street
New York
$957K +$555K +186,134 +982%
AI
31
Atom Investors
Texas
$877K +$220K +73,678 +65%
William Blair & Company
32
William Blair & Company
Illinois
$823K -$298K -100,000 -36%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$818K +$444K +148,725 +565%
Squarepoint
34
Squarepoint
New York
$799K +$510K +171,161 New
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$758K +$372K +124,683 +331%
Simplex Trading
36
Simplex Trading
Illinois
$740K +$228K +76,355 +93%
SEI Investments
37
SEI Investments
Pennsylvania
$658K +$420K +140,844 New
Northern Trust
38
Northern Trust
Illinois
$627K -$4.5K -1,508 -1%
Group One Trading
39
Group One Trading
Illinois
$591K -$602K -201,690 -61%
Citadel Advisors
40
Citadel Advisors
Florida
$476K +$238K +79,790 +361%
LA
41
Lakeside Advisors
Washington
$457K – – –
Citigroup
42
Citigroup
New York
$385K +$246K +82,418 New
OQS
43
Occudo Quantitative Strategies
Florida
$383K +$244K +81,941 New
ECM
44
ExodusPoint Capital Management
New York
$378K +$241K +80,916 New
AA
45
Advisory Alpha
Michigan
$368K – – –
Morgan Stanley
46
Morgan Stanley
New York
$338K -$81.4K -27,289 -27%
LP
47
LMR Partners
United Kingdom
$336K +$214K +71,918 New
JGC
48
J. Goldman & Co
New York
$333K +$213K +71,343 New
Belvedere Trading
49
Belvedere Trading
Illinois
$270K +$170K +57,164 New
Wolverine Trading
50
Wolverine Trading
Illinois
$236K +$86.7K +29,063 +160%
1
2
3 4

CTIC Hedge Fund Activity: Q1 2022 in Review

92 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2022, worth a combined $334M — up 183% from $118M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new CTIC positions and 4 closed out — a net gain of 29 holders — while 24 added to existing stakes and 18 trimmed.

The largest buyer was Lion Point Capital, adding an estimated $12.7M. The largest seller was Stonepine Capital Management, cutting an estimated $12.3M.

  • 92 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2022, up from 63 in Q4 2021.
  • Funds reported $334M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2022, up 183% quarter-over-quarter.
  • 33 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2022 and 4 closed out, a net change of +29 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2022 was Lion Point Capital, an estimated $12.7M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2022 was Stonepine Capital Management, an estimated $12.3M sold.

Based on aggregated 13F filings for Q1 2022.